Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
1. A composition, comprising:
liposomes comprised of compounds encapsulating a pharmaceutically active drug, wherein the liposomes are unilamellar, and comprised of phospholipids and cholesterol;
a pharmaceutically active free drug;
a pharmaceutically acceptable excipient; and
a polysorbate surfactant which interacts with the liposomes to reduce drug encapsulation and increase drug release from the liposomes;
wherein the weight ratio of polysorbate surfactant to liposomes is from 1:20 to 1:4;
wherein the surfactant causes an increase in drug release rate from the liposomes of about 5% to 50% as measured by an IVR assay.
2. The composition of claim 1 , wherein the composition is aerosolized into particles of formulation for inhalation into a human lung.
3. The composition of claim 1 wherein the composition is aerosolized into particles having an aerodynamic diameter in a range of 0.5 μm to 12 μm.
4. The composition of claim 3 , wherein the pharmaceutically active drug is an anti-infective.
5. The composition of claim 4 , wherein the anti-infective is ciprofloxacin.
6. The composition of claim 4 , wherein the anti-infective is selected from the group consisting of a quinolone, a sulfonamide, an aminoglycoside, a tetracycline, para-aminobenzoic acid, a diaminopyrimidine, a beta-lactam, a beta-lactam and a beta-lactamase inhibitor, chloramphenicol, a macrolide, lincomycin, clindamycin, spectinomycin, polymyxin B, colistin, vancomycin, bacitracin, isoniazid, rifampin, ethambutol, ethionamide, aminosalicylic acid, cycloserine, capreomycin, a sulfone, clofazimine, thalidomide, polyene antifungal, flucytosine, imidazole, triazole, griseofulvin, terconazole, butoconazole ciclopirax, ciclopirox olamine, haloprogin, tolnaftate, naftifine, and terbinafine.
7. The composition of claim 1 , wherein the formulation provide a rate of release of encapsulated drug between 2 and 10% per hour, with the near complete release of drug occurring after about 1 to 24 hours and the surfactant is polysorbate 20.
8. The composition of claim 7 , wherein the surfactant interacts with the liposome resulting in an increase in free drug of 1 to 50%.
9. A method of treating or ameliorating a P. aeruginosa infection, comprising:
aerosolizing a composition comprised of unilamellar liposomes comprised of phospholipids and cholesterol encapsulating ciprofloxacin to create aerosolized particles having an aerodynamic diameter in a range of 0.5 microns to 12 microns; and
allowing the particles to be inhaled;
wherein the composition further comprises:
free ciprofloxacin;
a pharmaceutically acceptable excipient; and
a polysorbate surfactant which interacts with the liposomes to reduce encapsulation of the ciprofloxacin and modulate release of the ciprofloxacin from the liposomes; and
wherein the polysorbate surfactant interacts with the liposomes in a manner which cause the liposomes to increase their ciprofloxacin release rate by 20% to 200% as measured by an IVR assay.
10. The method of claim 9 , wherein the ratio of polysorbate surfactant to liposomes by volume is between about 1:100 and 1:2.
11. The method of claim 9 , wherein the polysorbate surfactant interacts with the liposomes causing a release of ciprofloxacin from the liposomes thereby increasing the amount of free ciprofloxacin by 1 to 50%.
12. A method of modulating a drug release rate of a formulation, comprising:
providing a formulation comprised of a pharmaceutically acceptable carrier and liposomes, wherein the liposomes are comprised of a drug and phosphatidylcholine;
adding polysorbate 20 to the formulation in an amount of 0.1 to 1% by volume thereby increasing a drug release profile of the liposomes.
13. The method of claim 12 , further comprising:
administering the formulation to a patient; and
adjusting the amount of polysorbate 20 added based on a characteristic of the patient.
14. The method of claim 13 , wherein the formulation is administered by inhalation and the patient characteristic is lung function.
15. The method of claim 13 , wherein the patient characteristic is selected from the group consisting of body mass, lean body mass, height, age, gender, renal clearance assessment, liver function assessment, and determined concentration of the drug in patient blood.
16. The method of claim 13 , wherein the patient characteristic is selected from the group consisting of side effects observed, type of patient infection being treated, and known minimum inhibitory concentrations for the drug.